Skip to content

PTSD research published in 2025

Page 5 of 6: studies 81 to 100 of 118, newest first. Back to the PTSD overview

Studies

Mindful Self-Compassion for Veterans with Morally Injurious Experiences and Co-Occurring Posttraumatic Stress Disorder and Substance Use Disorder: A Feasibility Study.

Journal of dual diagnosis April 1, 2025 Erica Eaton, Christy Capone, Shannon Reese et al. 2 citations

Objective: This study evaluates the feasibility and acceptability of delivering Mindful Self-Compassion (MSC) to veterans with moral injury and co-occurring PTSD and substance use disorder (PTSD-SUD). Methods: Veterans (N = 26; M age = 50.92; 100% male) were recruited for an 8-week MSC group. Participants completed measures of self-compassion, guilt, shame, PTSD, and substance use outcomes at...

Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.

Social Work April 1, 2025 Maha N. Mian, Jordan Horan, Taweh Hunter et al. 1 citation

Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two...

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.

CNS Drugs April 1, 2025 Balwinder Singh 6 citations

Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recover, a subset develop post-traumatic stress disorder (PTSD), a debilitating condition characterized by distressing memories, avoidance behaviors, hyperarousal, and mood disturbances. The National Comorbidity Survey reports a lifetime PTSD prevalence...

Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses.

Australian & New Zealand Journal of Psychiatry April 1, 2025 Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani et al. 16 citations

To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder. Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted...

Digital Cognitive Behavioral Therapy-Based Treatment for Insomnia, Nightmares, and Posttraumatic Stress Disorder Symptoms in Survivors of Wildfires: Pilot Randomized Feasibility Trial.

JMIR human factors March 14, 2025 Fadia Isaac, Britt Klein, Huy Nguyen et al.

Symptoms of insomnia, nightmares, and trauma are highly prevalent. However, there are significant barriers to accessing evidence-based treatments for these conditions, leading to poor mental health outcomes. This pilot trial evaluated the feasibility of a 4-week, digital self-paced intervention combining cognitive behavioral therapy for insomnia and exposure, relaxation, and rescripting therapy...

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

medRxiv Preprint Server March 2, 2025 Bonnie L. Quigley, Emerald Orr, Sophie Kafka et al. preprint

Ketamine has been investigated as a treatment alternative for PTSD for the last 20 years, yet there have been virtually no reports of biological changes or biomarker characterisation related to treatment. To address this significant gap, this study analysed blood samples from 25 participants with PTSD who took part in an open-label 6-week trial of low dose oral ketamine treatment. Serum and...

Clinical indicators of the suicide crisis and response to ketamine.

Journal of Affective Disorders March 1, 2025 Elizabeth D. Ballard, Lucinda Neely, Laura Waldman et al. 4 citations

This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation at the time of suicide crisis and responsiveness to rapid-acting interventions. Suicidal ideation (SI), depression, and hopelessness were hypothesized to meet these criteria. Participants were 118 adults across the continuum of suicide risk, including...

Treating Post-Traumatic Stress Disorder in Canadian Special Operation Forces Command With Ketamine Plus Cervical Sympathetic Blockade.

Military Medicine February 27, 2025 Eugene Lipov, Hunter Rolain, Troy Neufeld 1 citation

Canadian Special Operation Forces Command (CANSOFCOM) operators have been extensively deployed in recent conflicts. They are at risk of trauma and blast exposure as well as the development of post-traumatic stress disorder (PTSD) and blast traumatic brain injury (bTBI). Current psychotherapy and pharmacological approaches provide suboptimal resolution of PTSD and bTBI symptoms. Prior research...

DOI: 10.1093/milmed/usaf051 (opens in new tab) Full text (opens in new tab) PTSD-Treatment Military-medicine Ketamine-therapy Combat-trauma +1

Treatment Approaches for Posttraumatic Stress Disorder Derived From Basic Research on Fear Extinction.

Biological Psychiatry February 15, 2025 Jessica L Maples-Keller, Laura E Watkins, Natalie Hellman et al. 12 citations

This brief review article will describe treatment approaches for posttraumatic stress disorder (PTSD) based on findings from basic research. The focus of this review will be fear conditioning and extinction models, which provide a translational model of PTSD that can help translate basic research in nonhuman animals through well-controlled trials confirming the efficacy of treatment approaches...

DOI: 10.1016/j.biopsych.2024.07.010 (opens in new tab) Full text (opens in new tab) Combination treatment Exposure therapy Fear extinction Translational +5

SLOW BUT STEADY: ORAL KETAMINE AS AN EFFECTIVE ADJUNCT IN DEPRESSION, ANXIETY AND PTSD

The International Journal of Neuropsychopharmacology February 12, 2025 *William Sulis

Abstract Intravenous and intranasal Ketamine have become important options for the rapid relief of symptoms in PTSD, Suicidality and in Treatment Resistant Depression and Anxiety. However, they are costly, require at least an out- patient clinic setting and have relatively short lived benefits. I present a pilot study examining 8 patients treated with oral Ketamine, 5 mg/kg for 12 treatments....

Hypnosis applications to the treatment of posttraumatic stress disorder.

American Journal of Clinical Hypnosis February 5, 2025 Kaloyan S. Tanev, Carolyn Daitch 1 citation

Current evidence-based therapies considered efficacious for posttraumatic stress disorder (PTSD) include Prolonged Exposure Therapy (PE), Cognitive Processing Therapy (CPT), Eye Movement Desensitization Reprocessing (EMDR), and medication treatments. Hypnosis, one of the first mind-body therapies known to Western medicine, has been used for mind-body problems such as conversion reactions,...

Post-traumatic stress disorder: evolving conceptualization and evidence, and future research directions.

World Psychiatry February 1, 2025 Chris R Brewin, Lukoye Atwoli, Jonathan I Bisson et al. 73 citations

The understanding of responses to traumatic events has been greatly influenced by the introduction of the diagnosis of post-traumatic stress disorder (PTSD). In this paper we review the initial versions of the diagnostic criteria for this condition and the associated epidemiological findings, including sociocultural differences. We consider evidence for post-traumatic reactions occurring in...

DOI: 10.1002/wps.21269 (opens in new tab) Full text (opens in new tab) Post‐traumatic stress disorder Community‐based interventions Complex PTSD Genetics +9

Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.

European Neuropsychopharmacology February 1, 2025 Danica E. Johnson, Nelson B Rodrigues, Sydney Weisz et al.

Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients...

The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD.

Contemporary Clinical Trials Communications February 1, 2025 Jessica L Maples-Keller, Boadie W Dunlop, Barbara O Rothbaum 5 citations

This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale...

Centering prayer in the treatment of Post-Traumatic Stress Disorder (PTSD)

World Journal of Advanced Research and Reviews January 30, 2025 Yanín Machado, Mauricio Chinchilla, Calixto Machado et al.

Post-traumatic stress disorder (PTSD) is a mental and behavioral disorder that develops from experiencing a traumatic event. A significant proportion of sexual assault survivors develop PTSD. Research indicates that 75% of sexual assault survivors meet the criteria for PTSD one month after the assault. PTSD treatment combines psychotherapy, medication, hypnosis, meditation, and emerging...

MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.

CNS Spectrums January 30, 2025 Steve O'Brien, David Nutt 5 citations

This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds...

A Quantitative and Qualitative Analysis of the Patient and Caregiver's Perspective on Outcomes of Intravenous Administration of Low-Dose Ketamine for C-PTSD, TBI, and Treatment Resistant MDD: A Clinical Example.

Reports (MDPI) January 22, 2025 Laura Hentig, James Hentig, Jessica M Gill 1 citation

Background and Clinical Significance: Treatment resistant psychiatric disorders affect millions of people across the globe. Ketamine has been employed as a treatment option for those with treatment resistant depression, as well as for chronic pain and alcohol use disorder. However, case presentations and research has been limited on the outcomes, and furthermore there is even less on the...

DOI: 10.3390/reports8010013 (opens in new tab) Full text (opens in new tab) Ketamine therapy Treatment-resistant depression trd Highly beneficial Significant positive shifts +4

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

PLoS One January 17, 2025 Shakila Meshkat, Wendy Lou, Rakesh Jetly et al. 10 citations

Background Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches. Preliminary evidence supports the potential therapeutic action...

DOI: 10.1371/journal.pone.0313741 (opens in new tab) Psilocybin Posttraumatic stress Cognition Cognitive processing therapy +2

Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.

ACS Medicinal Chemistry Letters January 9, 2025 Ram W. Sabnis 7 citations

Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.

Mindfulness-Oriented Professional Resilience (MOPR) Training to Reduce Compassion Fatigue in Healthcare Workers: A Pilot Study.

Healthcare January 7, 2025 Fabio D'Antoni, Alessio Matiz, Cristiano Crescentini

Background/Objectives: Compassion Fatigue (CF) is a critical issue among healthcare professionals, exacerbated by exposure to trauma and chronic workplace stress. This pilot study evaluates the effectiveness of a Mindfulness-Oriented Professional Resilience (MOPR) program, a structured intervention designed to mitigate CF and enhance resilience in healthcare professionals. The program...